Other
Neoplasm by Special Category
CI-CAN-00000004Explore in graph →
Non-malignant21,349 active trials259 approved drugs3,859 evidence items
- NCIt
- C7062
Loading cancer entity…
Loading cancer entity…
Other
CI-CAN-00000004Explore in graph →
Clinical trials
95,726 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05605197 | U87 CART in Treatment of Advanced Solid Tumor | unknown | Phase 1 | 12 | Shanghai Unicar-Therapy Bio-medicine Technology Co.,LtdINDUSTRY | 1 | May 28, 2024 | clinicaltrials |
| NCT04000906 | PIPAC With Nab-paclitaxel and Cisplatin in Peritoneal Carcinomatosis(Nab-PIPAC) | unknown | Phase 1 | 18 | University Hospital, GenevaOTHER | 1 | May 24, 2024 | clinicaltrials |
| NCT06427291 | Clinical Study of T3011 Intravesical Instillation for Treatment of NMIBC Patients | unknown | Phase 1 | 20 | Fudan UniversityOTHER | 1 | May 23, 2024 | clinicaltrials |
| NCT04092673 | Study of eFT226 in Subjects With Selected Advanced Solid Tumor Malignancies(Zotatifin) | unknown | Phase 1 / Phase 2 | 30 | Effector TherapeuticsINDUSTRY | 1 | May 21, 2024 | clinicaltrials |
| NCT05955105 | A Study of ILB2109 and Toripalimab in Patients With Advanced Solid Malignancies | unknown | Phase 1 / Phase 2 | 200 | Innolake BiopharmINDUSTRY | 1 | May 21, 2024 | clinicaltrials |
| NCT06421610 | OPC5: Pressurized IntraThoracic Aerosol Chemotherapy (PITAC) in Patients With Malignant Pleural Effusion. | unknown | Phase 1 | 20 | Odense University HospitalOTHER | 1 | May 20, 2024 | clinicaltrials |
| NCT03337087 | Liposomal Irinotecan, Fluorouracil, Leucovorin Calcium, and Rucaparib in Treating Patients With Metastatic Pancreatic, Colorectal, Gastroesophageal, or Biliary Cancer | unknown | Phase 1 / Phase 2 | 18 | Academic and Community Cancer Research UnitedOTHER | 1 | May 17, 2024 | clinicaltrials |
| NCT05564858 | A Study of FDA022-BB05 in Subjects With Advanced Solid Malignant Tumors | unknown | Phase 1 | 107 | Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.INDUSTRY | 1 | May 17, 2024 | clinicaltrials |
| NCT05650580 | TR115 in Patients With Relapsed / Refractory Non-Hodgkin's Lymphoma or Advanced Solid Tumors | unknown | Phase 1 | 26 | Tarapeutics Science Inc.INDUSTRY | 1 | May 14, 2024 | clinicaltrials |
| NCT05751356 | TR128 in Patients With Advanced Solid Tumors | unknown | Phase 1 | 50 | Tarapeutics Science Inc.INDUSTRY | 1 | May 14, 2024 | clinicaltrials |
| NCT06173999 | A Study of SHR2554 With Chemotherapy in Treatment-naïve Patients With Peripheral T-cell Lymphoma | unknown | Phase 1 / Phase 2 | 100 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | May 14, 2024 | clinicaltrials |
| NCT06412458 | IM83 Clinical Study of CAR-T Cell Therapy in Patients With Relapsed or Refractory Osteosarcoma | unknown | Phase 1 | 9 | Beijing Immunochina Medical Science & Technology Co., Ltd.INDUSTRY | 1 | May 14, 2024 | clinicaltrials |
| NCT05758610 | A Phase I Study of Euthare-155008(ETH-155008) in AML and NHL Patients | unknown | Phase 1 | 60 | Shengke Pharmaceuticals (Jiangsu) Limited, ChinaINDUSTRY | 1 | May 8, 2024 | clinicaltrials |
| NCT03292263 | ASCT With Nivolumab in Patients With Multiple Myeloma | unknown | Phase 1 / Phase 2 | 30 | St. Petersburg State Pavlov Medical UniversityOTHER | 1 | May 7, 2024 | clinicaltrials |
| NCT05354102 | A First-in-human (FIH) Combination Treatment Study With a Single Dose Level of BMC128 | unknown | Phase 1 | 11 | Biomica Ltd.INDUSTRY | 1 | May 7, 2024 | clinicaltrials |
| NCT04029181 | ImmunoPET With an Anti-CD8 Imaging Agent | unknown | Phase 1 / Phase 2 | 47 | University Medical Center GroningenOTHER | 1 | May 3, 2024 | clinicaltrials |
| NCT06081686 | Study of [177Lu] Lu-XT033 Injection in Patients With Metastatic Prostate Cancer | unknown | Phase 1 / Phase 2 | 32 | Sinotau Pharmaceutical GroupINDUSTRY | 1 | May 3, 2024 | clinicaltrials |
| NCT06395337 | Multimodal Imaging in Rectal Cancer & Pancreatic Cancer(MIRCA & MIPAC) | unknown | Phase 1 / Phase 2 | 20 | Radboud University Medical CenterOTHER | 1 | May 2, 2024 | clinicaltrials |
| NCT06394622 | A Clinical Research About CD70-targeted CAR-NKT Cells Therapy Advanced Malignant Solid Tumors | unknown | Phase 1 | 12 | Fudan UniversityOTHER | 1 | May 1, 2024 | clinicaltrials |
| NCT05804526 | A Study of RC88 Combined With Sintilimab for Advanced Solid Tumours | unknown | Phase 1 / Phase 2 | 82 | RemeGen Co., Ltd.INDUSTRY | 1 | Apr 30, 2024 | clinicaltrials |
| NCT05458544 | [Lu-177]Ludotadipep in Castration-resistant Prostate Cancer(CRPC): Investigation of Drug and Application(LUCIDA) | unknown | Phase 1 / Phase 2 | 26 | FutureChemINDUSTRY | 1 | Apr 29, 2024 | clinicaltrials |
| NCT04499339 | A Phase I/IIa Clinical Trial to Assess Feasibility, Safety and Antitumor Activity of Autologous SLAMF7 CAR-T Cells in Multiple Myeloma | unknown | Phase 1 / Phase 2 | 38 | Wuerzburg University HospitalOTHER | 3 | Apr 25, 2024 | clinicaltrials |
| NCT05865925 | Safety, Tolerability, Pharmacokinetics (PK), and Primary Clinical Efficacy of LY01616 in Patients With Advanced Solid Tumors | unknown | Phase 1 / Phase 2 | 78 | Luye Pharma Group Ltd.INDUSTRY | 1 | Apr 25, 2024 | clinicaltrials |
| NCT06384248 | Phase II Clinical Study of LTC004 in Patients With Advanced Sarcoma | unknown | Phase 1 / Phase 2 | 30 | LetolabINDUSTRY | 0 | Apr 25, 2024 | clinicaltrials |
| NCT05989724 | A First-in-Human Study of SON-DP in Participants With Relapsed/Refractory Intolerant to Standard of Care Therapies for Advanced/Metastatic Solid Tumors | unknown | Phase 1 | 150 | Qurgen Inc.INDUSTRY | 1 | Apr 24, 2024 | clinicaltrials |
| NCT06367673 | Natural Killer(NK) Cell Therapy Targeting CLL1 or CD33 in Acute Myeloid Leukemia | unknown | Phase 1 | 24 | Zhejiang UniversityOTHER | 1 | Apr 18, 2024 | clinicaltrials |
| NCT05735028 | The Efficacy and Safety of PD-1/PD-L1 Inhibitors Combined With Centipeda Minima (CM) in Lung Cancer | unknown | Phase 1 | 8 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Apr 17, 2024 | clinicaltrials |
| NCT05606380 | A Phase I Study to Investigate the Safety, Tolerability and PK of HLX60 (Anti-GARP Monoclonal Antibody) in Subjects With Solid Tumors or Lymphoma | unknown | Phase 1 | 11 | Shanghai Henlius BiotechINDUSTRY | 1 | Apr 16, 2024 | clinicaltrials |
| NCT06368960 | BM201 in Combination With Radiotherapy in Patients With Advanced Solid Tumors(BM201-1001) | unknown | Phase 1 | 36 | InnoBM Pharmaceuticals Co., Ltd.INDUSTRY | 1 | Apr 16, 2024 | clinicaltrials |
| NCT05240131 | A Study to Investigate the Safety and Efficacy of GB1211 (a Galectin-3 Inhibitor) in Combination With Atezolizumab in Patients With Non-Small Cell Lung Cancer (NSCLC). | unknown | Phase 1 / Phase 2 | 88 | Galecto Biotech ABINDUSTRY | 3 | Apr 12, 2024 | clinicaltrials |
| NCT05519293 | Phase I/IIa Study of H002 in NSCLC With Active EGFR Mutation | unknown | Phase 1 / Phase 2 | 76 | RedCloud BioINDUSTRY | 1 | Apr 11, 2024 | clinicaltrials |
| NCT05552781 | H002 in Patients With EGFR Mutation Locally Advanced or Metastatic NSCLC | unknown | Phase 1 / Phase 2 | 76 | RedCloud BioINDUSTRY | 1 | Apr 11, 2024 | clinicaltrials |
| NCT06308406 | A Phase Ib/II Clinical Study of HRS-1167 in Combination With Bevacizumab in Patients With Recurrent Ovarian Cancer | unknown | Phase 1 / Phase 2 | 54 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Apr 11, 2024 | clinicaltrials |
| NCT04469127 | A Phase I/II Multicenter, Open-Label Study of Lu-177-DOTAGA-IAC, for the Treatment of Angiogenic Breast Cancer Patients.(Heroine01) | unknown | Phase 1 / Phase 2 | 100 | Advanced Imaging Projects, LLCINDUSTRY | 2 | Apr 10, 2024 | clinicaltrials |
| NCT04032964 | Dose Finding Study of L19TNF and Doxorubicin in Patients With STS(DOXO75) | unknown | Phase 1 | 2 | Philogen S.p.A.INDUSTRY | 1 | Apr 8, 2024 | clinicaltrials |
| NCT04573192 | A Study to Evaluate Safety and Efficacy of L19TNF Plus Lomustine in Patients With Glioblastoma at First Progression(GLIOSTAR) | unknown | Phase 1 / Phase 2 | 142 | Philogen S.p.A.INDUSTRY | 4 | Apr 8, 2024 | clinicaltrials |
| NCT05064618 | Investigator-initiated Clinical Trial of MIKE-1(MIKE-1) | unknown | Phase 1 / Phase 2 | 55 | Nagoya UniversityOTHER | 1 | Apr 4, 2024 | clinicaltrials |
| NCT06348290 | Study to Evaluate the Drug-drug Interaction of JMKX001899 in Healthy Subjects | unknown | Phase 1 | 72 | JemincareINDUSTRY | 0 | Apr 4, 2024 | clinicaltrials |
| NCT04772235 | Phase I Study of Repotrectinib and Osimertinib in NSCLC Patients(TOTEM) | unknown | Phase 1 | 32 | Instituto Oncológico Dr RosellOTHER | 1 | Apr 3, 2024 | clinicaltrials |
| NCT06247657 | A Phase I Study to Assess the Safety and Tolerability of BL0006 for Patients With Advanced Solid Tumours | unknown | Phase 1 | 66 | Shanghai Best-Link Bioscience, LLCINDUSTRY | 1 | Apr 3, 2024 | clinicaltrials |
| NCT06344715 | Phase 1 Study Evaluating Safety and Tolerability of SL-T10, GX-I7, and Pembrolizumab Triple Combination in mCRPC. | unknown | Phase 1 | 78 | SL VAXiGENINDUSTRY | 1 | Apr 3, 2024 | clinicaltrials |
| NCT06241235 | Study of ZG005 in Combination With Paclitaxel＋Platinum-based ± Bevacizumab in Patients With Advanced Cervical Carcinoma | unknown | Phase 1 / Phase 2 | 48 | Suzhou Zelgen Biopharmaceuticals Co.,LtdINDUSTRY | 1 | Apr 2, 2024 | clinicaltrials |
| NCT05311618 | Study of NGM438 as Monotherapy and in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumors | unknown | Phase 1 | 71 | NGM Biopharmaceuticals, IncINDUSTRY | 1 | Apr 1, 2024 | clinicaltrials |
| NCT06328387 | HCQ+ADC vs ADC in the Treatment of Advanced Breast Cancer | unknown | Phase 1 / Phase 2 | 120 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | Mar 25, 2024 | clinicaltrials |
| NCT06279494 | Sirolimus+Abatacept+Mycophenolate Mofetil for Prophylaxis of aGVHD in Patients Receiving Haplo-HSCT Who Are Intolerant to Calcineurin Inhibitors | unknown | Phase 1 / Phase 2 | 6 | Peking University People's HospitalOTHER | 0 | Mar 21, 2024 | clinicaltrials |
| NCT06225622 | Dose Escalation and Expansion Clinical Trial of Irinotecan Liposome Combined With Oxaliplatin and 5-FU/LV Plus Bevacizumab as First-line Treatment of Metastatic Colorectal Cancer | unknown | Phase 1 | 78 | Shanghai Zhongshan HospitalOTHER | 1 | Mar 19, 2024 | clinicaltrials |
| NCT05646758 | A Clinical Trial of TQB2934 for Injection in Multiple Myeloma Subjects | unknown | Phase 1 | 140 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | Mar 18, 2024 | clinicaltrials |
| NCT03024489 | Palbociclib With Cetuximab and IMRT for Locally Advanced Squamous Cell Carcinoma | unknown | Phase 1 / Phase 2 | 27 | Mahidol UniversityOTHER | 1 | Mar 15, 2024 | clinicaltrials |
| NCT03291444 | CAR-T Cells Combined With Peptide Specific Dendritic Cell in Relapsed/Refractory Leukemia/MDS | unknown | Phase 1 | 30 | Zhujiang HospitalOTHER | 1 | Mar 15, 2024 | clinicaltrials |
| NCT04903873 | A Study to Evaluate Safety, Efficacy, and Pharmacokinetics in Participants With Advanced Solid Tumors | unknown | Phase 1 / Phase 2 | 110 | EutilexINDUSTRY | 2 | Mar 15, 2024 | clinicaltrials |
Data updated 23 days agoSource updated May 28, 2024source: clinicaltrials